Cancer drug dosing study could cut clinic visits in half

NCT ID NCT04295863

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether two common cancer immunotherapy drugs (nivolumab and pembrolizumab) can be given less often than the current standard schedule. About 264 adults with advanced or metastatic cancer will be randomly assigned to receive the drugs at standard intervals or extended intervals. Researchers will compare drug levels in the blood to see if the extended schedule keeps levels high enough to control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • SSM Health Cancer Care

    RECRUITING

    Madison, Wisconsin, 53717, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University Of Chicago Medicine Comprehensive Cancer Center

    RECRUITING

    Chicago, Illinois, 60637, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact